Table 5 Reason for end of follow-up in enrolled IPF patients
|  | Pirfenidone (N = 383) | No-antifibrotics (n = 218) | P-value (pirfenidone vs no-antifibrotics) |
|---|---|---|---|
Number of lost patients (%) | 141 (36.8%) | 161 (73.9%) | < 0.001 |
Deatha | 101 (26.4%) | 121 (55.5%) | < 0.001 |
< 12 months | 37 (9.7%) | 32 (14.7%) | < 0.001 |
12–24 months | 39 (10.2%) | 23 (10.6%) | |
> 24 months | 22 (5.7%) | 66 (30.3%) | |
Lost to follow-up | 24 (6.3%) | 33 (15.1%) | 0.001 |
< 12 months | 11 (2.9%) | 16 (7.3%) | 0.002 |
12–24 months | 9 (2.3%) | 7 (3.2%) | |
> 24 months | 4 (1.0%) | 10 (4.6%) | |
Lung transplantation | 7 (1.8%) | 0 (0.0%) | 0.052 |
< 12 months | 1 (0.3%) | 0 (0.0%) | 0.345 |
12–24 months | 2 (0.5%) | 0 (0.0%) | |
> 24 months | 4 (1.0%) | 0 (0.0%) | |
Other | 9 (2.3%) | 7 (3.2%) | 0.601 |
< 12 months | 4 (1.0%) | 3 (1.4%) | 0.885 |
12–24 months | 2 (0.5%) | 1 (0.5%) | |
> 24 months | 3 (0.8%) | 3 (1.4%) |